{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"groups":[{"description":"Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphomide;x 30 weeks; XRT.","id":"OG000","title":"UH-1"},{"description":"Window therapy of vincristine/irinotecan;Cyclophosphamide/carboplatin/etoposide;vincristine/doxorubicin/cyclophosphomide; x 30 weeks; XRT.","id":"OG001","title":"Window/UH-1"},{"description":"Window therapy of vincristine/irinotecan;Cyclophosphamide/carboplatin/etoposide; vincristine/doxorubicin/cyclophosphomide; x 36 weeks; XRT","id":"OG002","title":"UH-2"},{"description":"Vincristine/dactinomycin/doxorubicin x25 weeks; XRT","id":"OG003","title":"Regimen DD-4A"}],"populationDescription":"The analysis was supplanted by an analysis done as part of the TARGET initiative on NWTS-5 sample as a result no TP53 data was collected on AREN0321.","reportingStatus":"POSTED","timeFrame":"At baseline","title":"Frequency of TP53 Mutations","type":"SECONDARY"}